Skip to content

the effect of Xuefuzhuyu Decoction on the blood flow density and FAZ of RVO-ME after receiving anti-VEGF with OCTA

the effect of Xuefuzhuyu Decoction on the blood flow density and FAZ of RVO-ME after receiving anti-VEGF with OCTA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089976
Enrollment
Unknown
Registered
2024-09-20
Start date
2024-05-15
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

Basic treatment group:intravitreal injection
Comprehensive treatment group:intravitreal injection + Xuefuzhuyu decoction

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The results of slit lamp fundus examination, fundus color photography or fluorescein fundus angiography meet the diagnostic criteria of RVO; 2. TCM syndrome differentiation is qi stagnation and blood stasis syndrome; 3. Age 18-75 years, regardless of sex; 4. Can complete 3 months of treatment and follow-up; 5. The patient has fully understood and signed the I informed consent file; 6. Clear refractive stroma which do not affect fundus examination and OCTA examination; 7. The target eye did not receive any intravitreal anti-VEGF therapy in the first 3 months.

Exclusion criteria

Exclusion criteria: 1. People with other serious ophthalmic diseases, such as neovascular glaucoma and retinal detachment; 2. There are diseases that affect fundus examination, such as corneal scar, lens opacity, vitreous hemorrhage, etc. 3. There are other diseases that cause macular edema, such as diabetic retinopathy and age-related macular degeneration. 4. Active endophthalmitis or periocular infection; 5. It is judged by clinicians that fundus laser photocoagulation is needed immediately; 6. Preparing pregnant, pregnant or lactating women; 7. The test drug is known to be allergic to ingredients or allergic constitution; 8. Suffering from mental illness or unable to follow treatment plans, with poor compliance; 9. Patients who are currently enrolled in clinical trials for other drugs or have participated in any other clinical trials within the past three months; 10. Patients who are unable to cooperate with follow-up visits.

Design outcomes

Secondary

MeasureTime frame
central macular thickness;central retinal thickness;subfoveal choroidal thickness;best corrected visual acuity;

Primary

MeasureTime frame
foveal avascular zone;deep parafovea blood density ;

Countries

China

Contacts

Public ContactLi Huishan, Pang Long

The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine

susan1128@foxmail.com+86 135 7026 1822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026